Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms

Blood

Volumn 127, Issue 10, 2016, Pages 1307-1316

  Araki, Marito ^a   Yang, Yinjie ^a   Masubuchi, Nami ^a   Hironaka, Yumi ^a   Takei, Hiraku ^a   Morishita, Soji ^a   Mizukami, Yoshihisa ^a   Kan, Shin ^a   Shirane, Shuichi ^a   Edahiro, Yoko ^a   Sunami, Yoshitaka ^a   Ohsaka, Akimichi ^a   Komatsu, Norio ^a  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MUTANT PROTEIN; SHORT HAIRPIN RNA; STAT5 PROTEIN; THROMBOPOIETIN RECEPTOR; CALRETICULIN, HUMAN; JAK2 PROTEIN, HUMAN; MPL PROTEIN, HUMAN; THROMBOPOIETIN; TUMOR PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GAIN OF FUNCTION MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MEGAKARYOPOIESIS; MYELOPROLIFERATIVE NEOPLASM; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; GENETICS; HEK293 CELL LINE; HEMATOLOGIC DISEASE; INDUCED PLURIPOTENT STEM CELL; METABOLISM; MORTALITY; MYELOPROLIFERATIVE DISORDER; PATHOLOGY; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; THROMBOCYTOPOIESIS; TUMOR CELL LINE;

CALRETICULIN; CELL LINE, TUMOR; HEK293 CELLS; HEMATOLOGIC NEOPLASMS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; JANUS KINASE 2; MYELOPROLIFERATIVE DISORDERS; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, THROMBOPOIETIN; THROMBOPOIESIS; THROMBOPOIETIN;

EID: 84960906311     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-09-671172     Document Type: Article

References (27)

1. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-2390.
2. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369(25):2391-2405.
3. Rumi E, Pietra D, Ferretti V, et al; Associazione Italiana per La Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544-1551.
4. Shirane S, Araki M, Morishita S, et al. JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms. Haematologica. 2015;100(2):e46-e48.
5. Rotunno G, Mannarelli C, Guglielmelli P, et al; Associazione Italiana per La Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123(10):1552-1555.
6. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472-1477.
7. Fu R, Xuan M, Zhou Y, et al. Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: Clinical implications in diagnosis, prognosis and treatment. Leukemia. 2014;28(9):1912-1914.
8. Tefferi A, Lasho TL, Finke C, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: Differences in phenotype and prognostic impact. Leukemia. 2014;28(7):1568-1570.
9. Cleyrat C, Darehshouri A, Steinkamp MP, et al. Mpl traffics to the cell surface through conventional and unconventional routes. Traffic. 2014;15(9):961-982.
10. Komatsu N, Kunitama M, Yamada M, et al. Establishment and characterization of the thrombopoietin-dependent megakaryocytic cell line, UT-7/TPO. Blood. 1996;87(11): 4552-4560.
11. Komatsu N, Yamamoto M, Fujita H, et al. Establishment and characterization of an erythropoietin-dependent subline, UT-7/Epo, derived from human leukemia cell line, UT-7. Blood. 1993;82(2):456-464.
12. Sunami Y, Araki M, Hironaka Y, et al. Inhibition of the NAD-dependent protein deacetylase SIRT2 induces granulocytic differentiation in human leukemia cells. PLoS One. 2013;8(2):e57633.
13. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671-675.
14. Okita K, Yamakawa T, Matsumura Y, et al. An efficient nonviral method to generate integrationfree human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells. 2013;31(3):458-466.
15. Takayama N, Eto K. In vitro generation of megakaryocytes and platelets from human embryonic stem cells and induced pluripotent stem cells. Methods Mol Biol. 2012;788:205-217.
16. Komatsu N, Nakauchi H, Miwa A, et al. Establishment and characterization of a human leukemic cell line with megakaryocytic features: Dependency on granulocyte-macrophage colonystimulating factor, interleukin 3, or erythropoietin for growth and survival. Cancer Res. 1991;51(1): 341-348.
17. Hou W, Zhang Q, Yan Z, et al. Strange attractors: DAMPs and autophagy link tumor cell death and immunity. Cell Death Dis. 2013;4:e966.
18. Michalak M, Groenendyk J, Szabo E, Gold LI, Opas M. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem J. 2009;417(3):651-666.
19. Zamanian M, Veerakumarasivam A, Abdullah S, Rosli R. Calreticulin and cancer. Pathol Oncol Res. 2013;19(2):149-154.
20. Patel KP, Newberry KJ, Luthra R, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015;126(6):790-797.
21. Brooks AJ, Dai W, O'Mara ML, et al. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science. 2014;344(6185): 1249783.
22. Defour JP, Itaya M, Gryshkova V, et al. Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation. Proc Natl Acad Sci USA. 2013;110(7):2540-2545.
23. Dupuis M, Schaerer E, Krause KH, Tschopp J. The calcium-binding protein calreticulin is a major constituent of lytic granules in cytolytic T lymphocytes. J Exp Med. 1993;177(1):1-7.
24. Gold LI, Eggleton P, Sweetwyne MT, et al. Calreticulin: Non-endoplasmic reticulum functions in physiology and disease. FASEB J. 2010;24(3): 665-683.
25. Takei H, Morishita S, Araki M, et al. Establishment of iPS cells from myeloproliferative neoplasms patients with CALR mutation. Paper presented at the 77th Annual Meeting of the Japanese Society of Hematology. October 16-18, 2015. Kanazawa, Japan.
26. Waters MJ, Brooks AJ. JAK2 activation by growth hormone and other cytokines. Biochem J. 2015; 466(1):1-11.
27. Matthews EE, Thévenin D, Rogers JM, et al. Thrombopoietin receptor activation: Transmembrane helix dimerization, rotation, and allosteric modulation. FASEB J. 2011;25(7): 2234-2244.